A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, FOOD EFFECT, AND DRUG-DRUG INTERACTION OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERS
This research is looking at a new medicine called VENT-03, which could potentially help people with conditions like lupus. This is an early-stage study, meaning it's the very first time this medicine is being given to people. We are asking healthy volunteers to take part to help us understand if VENT-03 is safe and how their bodies react to it. We'll be giving different doses and observing carefully. We also want to see if food makes a difference to how the medicine works and if it interacts with other common medicines. This important first step helps us decide if the medicine is promising enough to test in people who actually have lupus in the future, with the aim of finding new and better treatments.
At a glance
What is this study about?
This study is focused on a new medicine called VENT-03. Imagine developing a completely new type of key to unlock a door. This study is like testing that new key for the very first time in a safe environment, before trying it on the actual door. We're giving VENT-03 to healthy volunteers, not people who are ill, to carefully check a few important things.
Firstly, and most importantly, we want to make sure it's safe. We'll be giving different doses to see if there are any side effects. We'll also be learning how your body handles the medicine – how quickly it gets into your system, how long it stays there, and how it's eventually removed. This helps us understand the right amount to give and how often.
We'll also look at how food might change these effects, and if taking VENT-03 at the same time as other common medicines could cause any issues. All this information is crucial for understanding if VENT-03 could be a useful treatment in the future, particularly for conditions like lupus, which is an illness where the body's immune system mistakenly attacks healthy tissues. Without early studies like this with healthy volunteers, we can't move forward to test medicines in people who need them most.
Key takeaways
- This is an early-stage study testing a new medicine (VENT-03) for the first time in healthy people.
- The main goals are to check the medicine's safety and how the body processes it.
- It aims to gather important information for future treatments of conditions like lupus.
- Participants will be healthy adults, both men and women, aged 18 and over.
- Participation involves taking the medicine (or placebo), clinic visits, and health monitoring.
- Your contribution helps advance medical science, but there's no direct health benefit from the medicine for healthy participants.
Who may be eligible?
This study is looking for healthy adults to take part. To be eligible, you need to be at least 18 years old. There is no upper age limit, meaning older adults are also welcome to participate if they meet other health criteria.
Both men and women can join this study. The main idea is to find people who are generally healthy, as this is the first time the new medicine is being tested in humans. This helps us understand the basic effects of the medicine without other health conditions making things complicated.
Detailed health checks will be done by the study team to make sure it's safe for you to take part. They will look at your medical history and do some tests to confirm you are healthy enough.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Are you able to attend clinic visits as required?
- Are you willing to potentially stay overnight for observation?
- Are you comfortable with blood tests and other medical checks?
What does participation involve?
If you decide to take part, you'll be given the new study medicine, VENT-03, in either single or multiple doses. You might also receive a placebo, which looks just like the study medicine but contains no active drug. This is done to help us compare the effects fairly. You won't know if you're getting the active medicine or the placebo, and neither will the study team.
Your participation will involve several visits to the clinic, and you might need to stay overnight on some occasions for observation. During these visits, the study team will take blood and urine samples and perform various checks to monitor your health and how your body reacts to the medicine. They will also look at how food affects the medicine and if it interacts with other common drugs. The total length of your participation, including follow-up, will be explained in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is lupus?
Lupus is a long-term condition where your body's immune system, which normally fights infections, mistakenly attacks your own healthy tissues and organs.
Why is this medicine being tested on healthy people first?
It's standard practice to test new medicines in healthy volunteers first to ensure they are safe and to understand how the body handles them, before giving them to people who are unwell.
What does 'randomized' mean?
It means you'll be randomly assigned to a group, like flipping a coin, to receive either the new medicine or a placebo, so the test is fair.
What is a 'placebo'?
A placebo looks exactly like the study medicine but doesn't contain any active drug. It helps compare the real effects of the medicine.
Will I get paid for taking part?
Many clinical trials offer some payment for your time and inconvenience. The study team will provide details on this.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.